In addition to drug products based on our proprietary delivery system, we have a portfolio of generic product candidates with favorable commercial agreements that supplement our branded pipeline.
ivermectin cream, 1%
Tentative Approval as of January 2018
acyclovir cream, 5%
Approval & Sales as of February 2019
5-fluorouracil cream, 5%
Bioequivalence Study Completed December 2019
In addition to advancing our lead product candidates, we are also engaged in the formulation and pre-clinical development of early stage innovative product candidates for both current focus indications, such as acne and rosacea, and for other dermatological indications.